Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

about

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.

P2860

Q38836158-856516CB-B833-4BCC-A856-AD751D7A1D6E

P2860

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

Item

http://www.wikidata.org/entity/Q38427102

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Metabolic disposition of AZD89 ...... gnalling, in rat, dog and man.

@en

type

Item

label

Metabolic disposition of AZD89 ...... gnalling, in rat, dog and man.

@en

prefLabel

Metabolic disposition of AZD89 ...... gnalling, in rat, dog and man.

@en

P1476

Metabolic disposition of AZD89 ...... gnalling, in rat, dog and man.

@en

P2093

Darren Wilbraham

http://www.w3.org/2001/XMLSchema#string

Helen C Swaisland

http://www.w3.org/2001/XMLSchema#string

Michael D Malone

http://www.w3.org/2001/XMLSchema#string

Peter Ballard

http://www.w3.org/2001/XMLSchema#string

Serban Ghiorghiu

http://www.w3.org/2001/XMLSchema#string

Sunil Sarda

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

EGFR antagonists in cancer treatment

EGF-ERBB signalling: towards the systems level

ERBB receptors and cancer: the complexity of targeted inhibitors

Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia.

Epidermal growth factor receptor: mechanisms of activation and signalling.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

The ErbB receptor tyrosine family as signal integrators.

EGFR and cancer prognosis.

P304

1083-1098

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2014.938257

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25007130

http://www.w3.org/2001/XMLSchema#string

P921

sapitinib

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

about

P2860

P2860

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921